Release Details
Sol-Gel Technologies to Participate in Upcoming LifeSci Partners Corporate Access Event and H.C. Wainwright BioConnect 2022 Healthcare Conference
Event details are as follows:
| Format | 1-on-1 meetings |
| Date: | |
| Registration | Link |
| H.C. Wainwright BioConnect 2022 Healthcare Conference | |
| Format | Webcast of corporate presentation |
| Date: | Webcast on demand starting at |
| Registration | Link |
About Sol-Gel Technologies
Sol-Gel is a dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. Sol‑Gel leverages its proprietary microencapsulation technology platform for TWYNEO, which is FDA approved for the treatment of acne vulgaris in adults and pediatric patients nine years of age and older; and EPSOLAY, under investigation for the treatment of inflammatory lesions of rosacea with an NDA filed with the FDA and a PDUFA goal date that was set for April 26, 2021. Action on the NDA for EPSOLAY has not yet been taken due to the inability of the FDA to conduct a pre‑approval inspection of the production site of EPSOLAY as a result of COVID‑19 travel restrictions. On
Contact:
Investor relations, LifeSci Advisors
[email protected]
+1 917 734 7387
Chief Financial Officer
[email protected]
Source: Sol-Gel Technologies Ltd.